GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,448.50p
   
  • Change Today:
    -14.50p
  • 52 Week High: 1,812.50p
  • 52 Week Low: 1,264.00p
  • Currency: UK Pounds
  • Shares Issued: 4,109.73m
  • Volume: 7,904,168
  • Market Cap: £59,530m
  • RiskGrade: 129

Latest ShareCast News

GSK's Nucala delivers positive outcomes in published trial results

By Josh White

Date: Thursday 01 May 2025

(Sharecast News) - GSK announced on Thursday that its monoclonal antibody 'Nucala', or mepolizumab, delivered a statistically significant and clinically meaningful reduction in exacerbations for patients with chronic obstructive pulmonary disease (COPD), according to final results from the phase three MATINEE trial published in the New England Journal of Medicine.

GSK ShareCast News

London close: Stocks finish higher as US economy... 30-Apr-2025 ShareCast
GSK confirms guidance after strong first quarter 30-Apr-2025 ShareCast
Two GSK vaccines get US CDC recommendations 17-Apr-2025 ShareCast
London close: Stocks fall as China retaliates to... 09-Apr-2025 ShareCast
London close: Stocks slide in global reaction to... 03-Apr-2025 ShareCast

GSK Regulatory News

Transaction in Own Shares 02-May-2025 07:00 RNS
Director/PDMR Shareholding 01-May-2025 15:30 RNS
Total Voting Rights 01-May-2025 15:00 RNS
Nucala MATINEE data in COPD published in NEJM 01-May-2025 07:00 RNS
Transaction in Own Shares 01-May-2025 07:00 RNS

GSK Newspaper Links

GSK ‘well positioned’ to cope with US pharmaceut... 30-Apr-2025 Times
GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent
GSK to cut hundreds of US jobs 01-Dec-2014 Telegraph
Ebola vaccine trials 'encouraging', says GSK 27-Nov-2014 Telegraph

GSK Tips & Analysis

Questor :GlaxoSmithKline 16-Apr-2014 Telegraph
Questor:GlaxoSmithKline 06-Oct-2011 Telegraph
Questor:GlaxoSmithKline 11-Aug-2011 Telegraph
Questor tip: GlaxoSmithKline 28-Jul-2011 Telegraph
Investment Column: GlaxoSmithKline 27-Jul-2011 The Independent

GSK News Wires

FDA Approves Promacta(R) (Eltrombopag), the Firs... 20-Nov-2008 PR Newswire
Study Found That Long Term Use of Advair Diskus(... 29-Oct-2008 PR Newswire
GlaxoSmithKline to Acquire Genelabs Technologies... 29-Oct-2008 PR Newswire
A New Interactive Consumer Experience Highlighti... 28-Sep-2007 PR Newswire
AUDIO from Medialink and GlaxoSmithKline: A New ... 28-Sep-2007 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,448.50p
Change Today -14.50p
% Change -0.99 %
52 Week High 1,812.50p
52 Week Low 1,264.00p
Volume 7,904,168
Shares Issued 4,109.73m
Market Cap £59,530m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
40.4% below the market average40.4% below the market average40.4% below the market average40.4% below the market average40.4% below the market average
Sector averageSector averageSector averageSector averageSector average
Price Trend
3.93% above the market average3.93% above the market average3.93% above the market average3.93% above the market average3.93% above the market average
45.83% above the sector average45.83% above the sector average45.83% above the sector average45.83% above the sector average45.83% above the sector average
Income
70.69% above the market average70.69% above the market average70.69% above the market average70.69% above the market average70.69% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
42.25% below the market average42.25% below the market average42.25% below the market average42.25% below the market average42.25% below the market average
37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 02-May-2025

Time Volume / Share Price
16:26 0 @ 1,449.00p
16:26 2 @ 1,449.00p
16:26 2 @ 1,449.00p
16:26 0 @ 1,449.00p
16:26 6 @ 1,449.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page